

Preface

The general description of the diverse benefits of *Moringa oleifera* tree is pretty ancient. Data relating to the beneficial constituents has been reported from around the world. Scientific researches have proven that this tree is in fact a powerful house of nutritional value. Thus, the plant can be considered as one of the best foods that can be found.

Besides, every part of the tree had been used effectively in folk remedies against a broad spectrum of ailments afflicting humankind, recent researches proved that basic idea, reports suggest the existence of antibiotic, anti inflammatory and anti tumor compounds which makes it an exceptional natural cure.

The benefit of Moringa tree is not restricted on health and promoting physiological well being; however, virtually every part of it is edible. It is used in industry, construction and in fighting against desertification.

Furthermore, suspensions of the ground seeds of the Moringa tree are used as primary coagulants. The use of natural materials of plant origin to clarify turbid surface water is not a new idea. Conversely, of all the plant materials that have been investigated over the years, the seeds from *M. oleifera* have been shown to be one of the most effective plants as a primary coagulant for water treatment.

The traditional use of the tree for domestic household water treatment has been limited to certain rural areas along the River Nile in Sudan. The people of these areas called it “Shagarat al rawag”.

Abstract

Given that the use of *Moringa* tree in Sudan is restricted on water treatment from visible impurities, though river water might be considered as a potential risk of infection.

Therefore, in this study, the aim was to detect and evaluate the antibacterial and antifungal activities that the *Moringa* tree parts, especially the seed kernels, might have.

The suitable clinical samples were collected, pathogens isolated, identified and purified for subsequent testing.

Based on global reports that suggest the existence of antimicrobial activity against a spectrum of microorganisms, a series of *in vitro* sensitivity tests were carried on 60 clinical isolates and 6 control strains (bacteria and fungi).

Results proved the hypothesis. An obvious antibacterial activity was found particularly in seed kernels. Among the control and clinical isolates; Gram positive bacteria were inhibited greater than Gram negative bacteria. *Staphylococcus aureus* showed the widest zones of inhibition comparatively with Norfloxacin antibiotic disc. On the other hand, antifungal activity was relatively weak in comparison with Nystatin and Clotrimazole antimycotic discs. Inhibition zones were created almost only by methanol and aqueous extracts of seeds. *Candida albicans* showed the widest zones of inhibition among the fungi tested.

In short, results obtained were successful and the extracts proved an observable antimicrobial activity.

الخلاصة

بما أن الإستعمال الوحيد لشجرة الرواق في السودان محصور علي تنقية مياه النيل من الرواسب المرئية العكر، وبما أن مياه النيل يمكن أن تكون مصدر لنقل عدوي الميكروبات الممرضة. لذلك، كان الهدف في هذه الدراسة هو تحديد و تقييم ما إذا كانت هناك خصائص مضاده للبكتيريا و الفطريات في بعض أجزاء شجرة الرواق، خاصة في لب البذور العينات الإكلينيكية المناسبة جمعت، الكائنات الممرضة عزلت، عرفت و صنفست للإستعمال في الإختبارات اللاحقه.

تم إجراء سلسله من إختبارات الحساسيه المعملية علي 60 معزولات سريره و 6 سلالات قياسيه (بكتريا و فطر) بناء علي بعض التقارير العالميه التي تقترح وجود نشاطات مضاده للجراثيم ضد مجموعه من الأحياء الدقيقه الممرضة.

النتائج أثبتت الفرضيه. تم إيجاد نشاطات مضاده للميكروبات بصوره واضحه، خاصه في لب البذور.

كما تم كبح البكتيريا موجبة الجرام بصوره أكبر من البكتيريا سالبة الجرام.

مقارنة بقرص النورفلوكساسين المضاد للجراثيم، المكوره العنقوديه الذهبية أظهرت أكبر منطقه كبح.

و في الجهه المقابله، النشاطات المضاده للفطريات كانت أضعف مقارنة بقرصي النستاتين و الكلوتريمازول المضاد للفطريات. مناطق

الكبح حدث في الأغلب بواسطة الخلاصات الميثانولية و المائيه للـ
البذور.
خميرة المبيضة البيضاء أظهرت أكبر مناطق كبح في ما بين
الفطريات المختبره
بإختصار, النتائج المتحصله كانت ناجحه, و الخلاصات أثبتت وجود نشاطات
واضحه مضاده للجراثيم

Dedication

To my father, the most considerate person ever,
To all who hold us in their hearts,
Thank you is less than enough.

Nada, July 2006

Acknowledgements

I would like to express my most appreciation to Prof. Aisha Zoheir Almagboul, for her sincere and generous support and supervision.

I am grateful to the staff in The Medicinal and Aromatic Plants Research Institute, whom lent me a hand in some practical aspects of the work, namely; the researchers Dr. Ashraf Nabeel Abdo Rabo and Mr. Hayder Abdel Gadir, and the technicians Mrs. Raja Altayeb and Mr. Modather Siddig.

I admire my friend Florina Uagoub, the laboratory scientist, who generously contributed her time and effort to facilitate some of the difficult times I've been through.

Special thanks are extended to the Dean of the faculty of Medical Laboratory Sciences of Sudan University Dr. Humodi Ahmed Saeed and to the Head of the Department Ustaz Omer Mohammed Khalel.

Table of Contents

Preliminaries:

Preface	ii
English	
Abstract	iii
Arabic	
Abstract	iv
Acknowledgements	vi
Table of	
Contents	vii
List of	
Tables	viii
List of	
Figures	ix
List of	
Charts	xi

List of Maps	
.....xii	

Chapter One:

Introduction and Rationale	
.....2	

Chapter Two:

Literature review	
.....15	
Objectives	
.....22	

Chapter Three:

Materials and Methods	
.....24	

Chapter Four:

Results and Discussion	
.....45	

Chapter Five:

Conclusion	
.....75	
Recommendations	
.....76	

Chapter Six:

References	
.....78	

List of Tables

Chapter One:

Table (1-1)	2
"Geography and life forms of the family <i>Moringaceae</i> ".	

Chapter Three:

Table (3-1)	34
"Zone diameter limits for control strains".	
Table (3-2)	36
"The weight and yield of different <i>Moringa oleifera</i> parts preparations".	
Table (3-3A)	37
"Dilution ratios of <i>Moringa oleifera</i> residues".	
Table (3-3B)	37
"Dilution ratios of <i>Moringa oleifera</i> residues".	
Table (3-4)	38
"The weight and yield of water preparations to fresh dry <i>M. oleifera</i> parts".	

Chapter Four:

Table (4-1)	46
"The selected standard antibiotic discs and their corresponding microbes".	
Table (4-2)	47

“Bacterial control strains vs. 1:10 dilutions of crude and fresh extracts”.	
Table (4-3)	
.....	49
“Bacterial control strains vs. 2:10 dilutions of crude and fresh extracts”.	
Table (4-4)	
.....	50
“Fungal control strains vs. 2:10 dilutions of crude and fresh extracts”.	
Table (4-5)	
.....	53
“Results of the control and clinically isolated <i>Staphylococcus aureus</i> ”.	
Tables (4-6) “Clinical isolates”	
.....	64, 65
Table (4-7) “Control strains”	
.....	65
Tables (4-8)	
.....	66, 67, 68
“Antimicrobial activity of crude and fresh extracts against clinical isolates”.	
Table (4-9) “Tests to identify G + ve cocci”	69
Tables (4-10) “Tests to identify G - ve rods”	70, 71

List of Figures

-

Chapter One:

Figure (1-1, 2, 3, 4)	6
“The flowers, leaves and pods of <i>Moringa oleifera</i> ”.	
Figure (1-5) “Ben oil”	7
Figure (1-6) “African living fence tree”	7
Figure (1-7) “The nutritional value of <i>Moringa</i> leaves”	8
Figure (1-8) “Flowers of <i>Moringa oleifera</i> ”	10
Figure (1-9) “Pods of <i>Moringa oleifera</i> ”	11
Figure (1-10) “Seeds kernel and cortex”	12

Chapter Two:

Figures (2-1 A, B, C) “ <i>Moringa</i> trees”	15
Figure (2-2)	16
“Turbidity samples following various stages of treatment”.	
Figure (2-3) “Coagulant materials”	19

Chapter Four:

Figure (4-1 A, B)	48
“Plates of STD no.3 <i>St. aureus</i> against plant preparations”.	
Figure (4-2 A, B)	48
“Plates of STD no.4 <i>Pr. mirabilis</i> against plant preparations”.	
Figure (4-3)	

.....,.....51	"Diagrammatic representation of culture media, bacterial growth, wells with drops of extracts and the inhibition zones".
Figure (4-4 A,	
B)	
.....,.....54	
"Plates of clinical isolate no.6 <i>St. aureus</i> against plant preparations".	
Figure (4-	
5)	
.....,.....54	
"Plates of clinical isolate no.11 <i>Streptococcus D</i> against plant preparations".	
Figure (4-6 A,	
B)	
.....,.....55	
"Plates of clinical isolate no.46 <i>Ps. aeruginosa</i> against plant preparations".	

Figure (4-	
7)	
.....,.....57	
"The sensitive strain <i>E- coli</i> against plant preparations".	
Figure (4-8 A,	
B)	
.....,.....59	
"Plates of clinical isolate no.5 <i>St. aureus</i> against plant preparations".	
Figure (4-9 A,	
B)	
.....,.....59	
"Double zones of inhibition".	
Figure (4-10 A,	
B)	
.....,.....60	

“Plates of clinical isolate no.3 <i>St. aureus</i> against plant preparations”.	
Figure (4-11)	62
“Plates of clinical isolate no.7 <i>St. aureus</i> against plant preparations”.	
Figure (4-12)	62
“Plates of clinical isolate no.40 <i>K. pneumoniae</i> against plant preparations”.	
Figure (4-13)	63
“The different zones of extract diffusion”.	
Figure (4-14 A, B)	72
“Plates of clinical isolate no.4 <i>St. aureus</i> against plant preparations”.	
Figure (4-15)	72
“Plates of clinical isolate no.2 <i>St. aureus</i> against plant preparations”.	
Figure (4-16)	72
“Plates of clinical isolate no.5 <i>St. aureus</i> against plant preparations”.	
Figure (4-17)	73
“Plates of clinical isolate no.42 <i>P. mallaei</i> against plant preparations”.	
Figure (4-18)	73
“Plates of clinical isolate no.24 <i>E- coli</i> against plant preparations”.	

Figure (4-19 A, B)	73
“Plates of clinical isolate no.39 <i>E- coli</i> against plant preparations”.	

List of Charts

Chapter Four:

Chart (4- 1)	49
“Control strains against the two dilutions of crude and fresh extracts”.	
Chart (4- 2).....	52
“Comparative presentation between the antibiotic Norfloxacin, the control and clinical isolates of <i>St. aureus</i> against all plant preparations”.	
Chart (4- 3).....	53
“Comparative presentation between the antibiotic Norfloxacin, the control and clinical isolates of <i>St. aureus</i> against the aqueous extract of seeds”.	
Chart (4- 4).....	56

“Comparative presentation between control strain and unique sensitive isolate: *E-coli*”.

Chart (4-5).....57

“Comparative presentation between control strain and unique sensitive isolate: *Ps. aeruginosa*”.

Chart (4-6).....58

“Comparative presentation between control strain and clinical isolates of *Candida albicans*”.

List of Maps

Chapter One:

Map (1-1)3

“Geographical distribution of *Moringa species*”.

Map (1-2)4

"The distribution of *Moringa* species in the Horn of Africa".
